Of note, because the SST2 display both anti‐proliferative and anti‐epileptic properties [43], our MRgFUS noninvasive approach could also be of particular interest to test the therapeutic values of SST2 agonists in preclinical models of brain tumours and epilepsy. Here, SSTR2 is linked to brain neoplasm.